Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia or Schizoaffective Clear all
Recruiting Phase 4 Interventional

Exercise and Olanzapine-samidorphan

NCT06740890
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions
Olanzapine-samidorphan + exercise
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 11, 2026, 9:51 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

NCT03669640
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
RO6889450, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Bellflower, California • Garden Grove, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Bioavailability of LY03004 and Risperdal® Consta®

NCT02091388
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LY03004, Risperdal® Consta®
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • Long Beach, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 3 Interventional

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCT00347425
View directory record Official record
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Lithium Drug-Drug Interaction Study With Lurasidone HCl

NCT01074073
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

NCT02504476
View directory record Official record
Conditions
Schizophrenia or Schizoaffective Disorder
Interventions
AMG 581, Placebo, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

NCT00406315
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
28
States / cities
Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Digoxin Drug-Drug Interaction With Lurasidone HCl

NCT01082289
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

NCT00061802
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
risperidone, quetiapine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Results available

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine Extended Release, Olanzapine Immediate Release
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Abilify Therapy for Reducing Comorbid Substance Abuse

NCT00208169
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
Interventions
Aripiprazole
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

NCT00512070
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
Interventions
olanzapine and melatonin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581

NCT02567370
View directory record Official record
Conditions
Schizophrenia or Schizoaffective Disorder
Interventions
AMG 581, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia

NCT00208143
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Substance Abuse, Substance Dependence
Interventions
Quetiapine, Risperidone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Sustainable Early Episode Clinic Study (SEEC)

NCT03571685
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sustainable Early Episode Clinic Model of Care
Behavioral
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 2Phase 3 Interventional

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

NCT00088465
View directory record Official record
Conditions
Schizophrenic Disorders, Schizoaffective Disorder
Interventions
Intramuscular olanzapine depot
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 76 Years
Enrollment
931 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
21
States / cities
Orange, California • Pasadena, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Jun 11, 2026, 9:51 AM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

NCT06627413
View directory record Official record
Conditions
Schizophrenia or Schizoaffective
Interventions
Lumateperone Capsule, Lumateperone LAI
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Los Alamitos, California • Atlanta, Georgia • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 11, 2026, 9:51 AM EDT
Terminated Not applicable Interventional Results available

Horyzons: Implementation and Integration in Clinical Practice

NCT06002958
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
Interventions
Horyzons USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

NCT04779177
View directory record Official record
Conditions
Schizophrenia, Pediatric
Interventions
Lumateperone 42 mg, Lumateperone 28 mg
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jun 11, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

NCT00538642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Jun 11, 2026, 9:51 AM EDT